Studies Show Psilocybin Therapy Has Potential For Anorexia Nervosa And Severe Treatment-Resistant Depression
May 18, 2022   

Recent positive data was announced from two investigator-initiated studies demonstrating the potential of COMP360, a psilocybin therapy for anorexia nervosa and severe treatment-resistant depression. These two studies provided support for continued research at a larger scale to elucidate the therapeutic potential of psilocybin...
 Continue reading
Factors Associated With Professional Mental Health Service Use Among Adults With Suicidal Ideation
May 16, 2022   

Fewer than half of people who die by suicide engage with mental health services in the year prior to death. However, few studies have examined which factors are associated with professional mental health services among people experiencing suicidal ideation. A cross-sectional survey study of...
 Continue reading (Members only)
Mental Health Impacts of Climate Change: Educational Toolkit
May 12, 2022   

Emerging research suggests that climate change will increase the prevalence of posttraumatic stress disorder, depression, anxiety, psychotic disorders, and suicide. An educational toolkit has been developed to empower students to think critically about structural inequalities that affect them and challenge the assumption that they do not have the capacity to overcome the sociopolitical issues that affect them...
 Continue reading (Members only)
FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022   

The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline...
 Continue reading (Members only)
Non-Invasive Brain Stimulation For Smoking Cessation
May 4, 2022   

A recent review and meta-analysis of randomized controlled trials of non-invasive brain stimulation for the treatment of tobacco use disorder found that non-invasive brain stimulation may improve smoking abstinence rates for up to 6 months after smoking cessation compared to control. Current smoking cessation rates with no medical intervention are approximately...
 Continue reading (Members only)
FDA Approves Nonstimulant Option For Adults With ADHD
April 29, 2022   

The U.S. Food and Drug Administration approved an expanded indication for viloxazine extended-release capsules for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 and older, making it the first novel, nonstimulant option for adults with ADHD in 20 years. ...
 Continue reading
Highlights From the 2022 NEI Synapse: Pain in the Presence of Psychiatric Comorbidities
April 24, 2022   

At the 2022 NEI Synapse, Dr. Andrew Cutler presented a practical and comprehensive lecture on treating chronic and neuropathic pain in the presence of psychiatric comorbidities.
 Continue reading
Highlights From the 2022 NEI Synapse: Depression Throughout the Female Lifespan
April 23, 2022   

At the 2022 NEI Synapse, Dr. Mary Kimmel discussed best practices for diagnosing and treating depression in women throughout their lives in a CME/CE session titled, “Ups and Downs: Diagnosing and Treating Depression Throughout the Female Lifespan.”
 Continue reading
Highlights From the 2022 NEI Synapse: Optimizing Treatment for Patients With Schizophrenia
April 22, 2022   

At the 2022 NEI Synapse, Dr. Leslie Citrome delivered multiple clinically relevant presentations that provided key practical takeaways for any clinician who is striving to optimize functioning for their patients with schizophrenia...
 Continue reading
Vortioxetine in Patients with Major Depressive and Alcohol Use Disorders
April 17, 2022   

Major depressive disorder (MDD) is often found comorbid with alcohol use disorder (AUD) and patients with MDD+AUD often have a worsened illness and prognosis. Response of MDD+AUD to classic antidepressants, including selective serotonin reuptake inhibitors (SSRIs), norepinephrine serotonin reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) is often unsatisfactory. In this study...
 Continue reading (Members only)
Top of Page